Cochlear (COH) 주식 개요코클리어는 전 세계 어린이와 성인을 위한 임플란트형 청각 솔루션을 제공합니다. 자세히 보기COH 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장1/6과거 실적2/6재무 건전성6/6배당3/6강점공정 가치 추정치보다 낮은 29.6% 에서 거래수익은 매년 7.39% 증가할 것으로 예상됩니다.위험 분석3.48% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.모든 위험 점검 보기COH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,720 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG487,720 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$124.1216.7% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-160m3b2016201920222025202620282031Revenue AU$2.9bEarnings AU$424.1mAdvancedSet Fair ValueView all narrativesCochlear Limited 경쟁사AnsellSymbol: ASX:ANNMarket cap: AU$4.4bRamsay Health CareSymbol: ASX:RHCMarket cap: AU$9.9bSonic HealthcareSymbol: ASX:SHLMarket cap: AU$10.6bAustco HealthcareSymbol: ASX:AHCMarket cap: AU$93.7m가격 이력 및 성과Cochlear 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가AU$124.1252주 최고가AU$319.5552주 최저가AU$88.76베타0.261개월 변동20.93%3개월 변동-28.12%1년 변동-59.08%3년 변동-45.55%5년 변동-48.26%IPO 이후 변동110.27%최근 뉴스 및 업데이트공시 • Feb 13Cochlear Limited Announces an Interim Franked Ordinary Dividend for the Six Months Ended December 31, 2025, Payable on 13 April 2026Cochlear Limited announced an interim franked ordinary dividend of AUD 2.15 per share has been determined for the six months ended December 31, 2025, in line with last year and representing a payout of 72% of underlying net profit. The interim dividend is franked at 85%. The ex-dividend date is 19 March 2026. The record date for calculating dividend entitlements is 20 March 2026 with the interim dividend expected to be paid on 13 April 2026. The ex-date is March 19, 2026, and the record date is March 20, 2026.공시 • Jan 08Cochlear Announces Availability of Nucleus Nexa System to Us Military VeteransCochlear announced that the Nucleus®? Nexa®? System is now available to eligible US military veterans at VA clinics nationwide. This milestone ensures that veterans with hearing loss have access to Cochlear's most innovative hearing technologies, designed to deliver smarter, more connected hearing experiences. The Nucleus Nexa System is the world's first smart cochlear implant system. The features include upgradeable firmware, internal memory, and with the Power Compact rechargeable battery, is the smallest and lightest sound processor with all day battery life on the market. Paired with the Nucleus 8 Nexa or Kanso®? 3 Nexa sound processors, the system offers intelligent performance that adjusts in real time to changing environments, helping users hear with clarity and comfort.공시 • Sep 22Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Non-Executive Director Caroline Clarke was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 15+ 1 more updateCochlear Limited to Report First Half, 2026 Results on Feb 13, 2026Cochlear Limited announced that they will report first half, 2026 results on Feb 13, 2026공시 • Aug 12Cochlear Limited, Annual General Meeting, Oct 23, 2025Cochlear Limited, Annual General Meeting, Oct 23, 2025. Location: hybrid meeting, Australia더 많은 업데이트 보기Recent updates공시 • Feb 13Cochlear Limited Announces an Interim Franked Ordinary Dividend for the Six Months Ended December 31, 2025, Payable on 13 April 2026Cochlear Limited announced an interim franked ordinary dividend of AUD 2.15 per share has been determined for the six months ended December 31, 2025, in line with last year and representing a payout of 72% of underlying net profit. The interim dividend is franked at 85%. The ex-dividend date is 19 March 2026. The record date for calculating dividend entitlements is 20 March 2026 with the interim dividend expected to be paid on 13 April 2026. The ex-date is March 19, 2026, and the record date is March 20, 2026.공시 • Jan 08Cochlear Announces Availability of Nucleus Nexa System to Us Military VeteransCochlear announced that the Nucleus®? Nexa®? System is now available to eligible US military veterans at VA clinics nationwide. This milestone ensures that veterans with hearing loss have access to Cochlear's most innovative hearing technologies, designed to deliver smarter, more connected hearing experiences. The Nucleus Nexa System is the world's first smart cochlear implant system. The features include upgradeable firmware, internal memory, and with the Power Compact rechargeable battery, is the smallest and lightest sound processor with all day battery life on the market. Paired with the Nucleus 8 Nexa or Kanso®? 3 Nexa sound processors, the system offers intelligent performance that adjusts in real time to changing environments, helping users hear with clarity and comfort.공시 • Sep 22Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Non-Executive Director Caroline Clarke was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Aug 15+ 1 more updateCochlear Limited to Report First Half, 2026 Results on Feb 13, 2026Cochlear Limited announced that they will report first half, 2026 results on Feb 13, 2026공시 • Aug 12Cochlear Limited, Annual General Meeting, Oct 23, 2025Cochlear Limited, Annual General Meeting, Oct 23, 2025. Location: hybrid meeting, Australia공시 • Jul 08Cochlear Limited Launches Smart Cochlear Implant SystemCochlear Limited announced the U.S Food and Drug Administration (FDA) approval of the Cochlear™? Nucleus®? Nexa™? System - the world's first and only smart cochlear implant system. Until now, recipients of cochlear implants have been limited to accessing new technology through the external part of their cochlear implant system - the sound processor - and have typically needed a new sound processor to fully experience the benefits of new technology. The new smart Nexa System has upgradeable implant firmware, which for the first time will enable Cochlear recipients to access future innovation through both their implant and sound processor. Recipients will now have access to their best possible hearing experience with both implant and sound processor updates. The Nucleus Nexa System builds upon Cochlear's portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of hearing performance and opens the door to even greater hearing potential for patients into the future.공시 • Jun 03Cochlear Limited Introduces the Baha®? 7 Sound Processor and Baha SoundBandCochlear Limited announced the commercial release of the new Cochlear™? Baha®? 7 Sound Processor and the new non-surgical Baha SoundBand™. Cochlear's bone conduction hearing solutions are designed to improve hearing outcomes for children and adults with conductive hearing loss, mixed hearing loss and single-sided deafness (SSD). The Baha 7 Sound Processor builds upon the same great hearing performance of its predecessor while advancing Cochlear's connectivity. The Baha 7 Sound Processor boasts a 55 db HL fitting range in a small form factor, offering powerful hearing without compromising on discretion. With new Bluetooth LE Audio and Auracast broadcast audio compatibility, the Baha 7 Sound Processor leads the hearing implant industry in streaming technology. As more venues adopt Auracast technology, Baha 7 Sound Processor recipients can access audio streams in places like theaters, concert halls, lecture halls and airports, through an LE Audio-enabled smartphone. The Baha 7 Sound processor is also able to stream directly from any compatible Apple® and Android™ device, as well as a range of wireless accessories. non-surgical Baha Start portfolio now includes the Baha 7 Sound Processor and the new Baha SoundBand. Baha Start is designed to help babies and young children experience the fullness of clear, rich and natural sound as early as possible. Early access to sound is critical to helping children learn and develop on par with their hearing peers. The new SoundBand features a slimmer band with improved adjustability, a lower profile, moveable connector discs and more color options to help young children be as comfortable and confident as possible. The Baha Smart App®? and Baha Fitting Software 7 also have new features aimed to help parents and clinicians treat children for the best possible hearing outcomes. The Baha 7 sound Processor and Baha SoundBand will be available in the United States in late summer 2025.Declared Dividend • Feb 16First half dividend of AU$2.15 announcedShareholders will receive a dividend of AU$2.15. Ex-date: 20th March 2025 Payment date: 14th April 2025 Dividend yield will be 1.6%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (75% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 15First half 2025 earnings released: EPS: AU$3.13 (vs AU$2.92 in 1H 2024)First half 2025 results: EPS: AU$3.13 (up from AU$2.92 in 1H 2024). Revenue: AU$1.17b (up 6.7% from 1H 2024). Net income: AU$205.1m (up 7.2% from 1H 2024). Profit margin: 18% (in line with 1H 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 11% per year.공시 • Feb 15Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended December 31, 2024, Payable on April 14, 2025Cochlear Limited announced ordinary dividend of AUD 2.15000000 per security for the period of six months ended December 31, 2024. Record date: March 21, 2025. Ex-date: March 20, 2025. Payment date: April 14, 2025.Buy Or Sell Opportunity • Feb 12Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 3.4% to AU$306. The fair value is estimated to be AU$252, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.9%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Buy Or Sell Opportunity • Oct 01Now 20% overvaluedOver the last 90 days, the stock has fallen 7.3% to AU$292. The fair value is estimated to be AU$243, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.9%. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.공시 • Sep 19+ 1 more updateStu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025Cochlear Limited announced that Stu Sayers, current CFO, will be appointed President, Asia Pacific & Latin America from 1 January 2025.Upcoming Dividend • Sep 10Upcoming dividend of AU$2.10 per shareEligible shareholders must have bought the stock before 17 September 2024. Payment date: 10 October 2024. Payout ratio and cash payout ratio are on the higher end at 75% and 82% respectively. Trailing yield: 1.5%. Lower than top quartile of Australian dividend payers (6.1%). In line with average of industry peers (1.6%).공시 • Aug 17+ 1 more updateCochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024Cochlear Limited announced ordinary dividend of AUD 2.10000000 per security for the period of six months ended June 30, 2024. Ex Date is September 17, 2024; Record Date is September 18, 2024; Payment Date is October 10, 2024.공시 • Aug 15Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.Cochlear Limited (ASX:COH) announces a share repurchase program. Under the program, the company will repurchase up to AUD 75 million worth of its ordinary shares. The program will expire on August 28, 2025. As of August 15, 2024, the company has 65,494,231 shares in issue.Reported Earnings • Aug 15Full year 2024 earnings released: EPS: AU$5.45 (vs AU$4.57 in FY 2023)Full year 2024 results: EPS: AU$5.45 (up from AU$4.57 in FY 2023). Revenue: AU$2.24b (up 16% from FY 2023). Net income: AU$356.8m (up 19% from FY 2023). Profit margin: 16% (in line with FY 2023). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 7% per year.공시 • Aug 15+ 1 more updateCochlear Limited, Annual General Meeting, Oct 25, 2024Cochlear Limited, Annual General Meeting, Oct 25, 2024. Location: will be held as a hybrid, Australia공시 • Jul 30Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024Cochlear Limited (Cochlear) announced the appointment of Caroline Clarke to the Cochlear Board. Ms. Clarke's appointment as a Non-Executive Director will become effective on 2 September 2024. Ms. Clarke has more than 30 years of commercial experience, including 20 years of executive leadership roles at medical devices, medical equipment and healthcare services businesses in large global companies. Ms. Clarke was most recently CEO and Executive Vice President ASEAN Pacific for Philips, responsible for the overall strategy, business and management of the Health Systems and Consumer Personal Health businesses in 14 countries across the region. Caroline is an impressive, people-oriented business leader, driven by making a meaningful impact by improving lives and has demonstrable experience in partnering with leading healthcare institutions to deliver new solutions. Her rounded experience and skills will be invaluable to Cochlear and serve to further enhance the expertise of the Board. Ms. Clarke will become a member of the People and Culture Committee, the Product & Services Innovation Committee and the Nomination Committee. Ms. Clarke holds a bachelor's degree in Business Studies, is a graduate of the Harvard Business School's Advanced Management Program and the Australian Institute of Company Directors, and resides in Sydney, Australia.공시 • Jul 26Cochlear Limited Announces Executive ChangesCochlear Limited announced a number of changes to the executive team. Richard Brook will be stepping down as President, Europe and Middle East and Africa (EMEA) at the end of December 2024 after more than 20 years in the role. Richard has overseen a period of substantial growth for EMEA, with an eight-fold increase in revenue during that time. Anthony Bishop, current President, Asia Pacific & Latin America, will be appointed President, EMEA from 1 January 2025. Anthony was appointed President, Asia Pacific in July 2016 and took on responsibility for Latin America in June 2021. He has been responsible for the development and execution of the strategic direction for all its operations in Australia, Asia, the South Pacific and Latin America. Prior to Cochlear, Anthony spent 21 years at Johnson & Johnson Medical in various roles, including marketing, sales and general management around the world, including Managing Director, Johnson & Johnson Medical, Australia/New Zealand. Stu Sayers, current Chief Financial Officer, will be appointed President, Asia Pacific & Latin America from 1 January 2025. Stu was appointed as Chief Financial Officer in February 2021 and was previously President, Services since joining Cochlear in July 2016. Prior to Cochlear, Stu led Amazon's subsidiary Audible in Asia Pacific, as well as E*TRADE and Yahoo!7 in Australia and New Zealand. He previously held senior roles with ANZ and McKinsey.공시 • May 22+ 1 more updateCochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).Cochlear Limited (ASX:COH) agreed to acquire Oticon Medical A/s from Demant A/S (CPSE:DEMANT) for DKK 850 million on April 27, 2022. Of the total consideration of DKK 850 million, DKK 700 million will be paid in cash at closing and DKK 150 million within 18 months after closing. In 2021, Oticon realized revenue of DKK 512 million and Negative EBIT of DKK 117 million. Subject to regulatory approvals and other customary closing conditions and receipt of competition approval. The acquisition is conditional upon approval from each of the CMA, the Australian Competition and Consumer Commission and the European Commission. On October 11, 2022 the CMA launched its phase 1 merger investigation for the acquisition of Oticon Medical A/S. The transaction is expected to close in second half of 2022, following consultation of relevant workers’ councils. As of December 1, 2022, The ACCC has advised a provisional final decision date of March 16, 2023. As on December 7, 2022, The CMA’s competition concerns only relate to the supply of bone conduction solutions in the UK and do not relate to the supply of cochlear implants. Cochlear and Demant have until 13 December to submit undertakings to address the CMA’s competition concerns. As of December 20, 2022, Competition and Markets Authority decided to refer this Merger for a phase 2 investigation. As of April 20, 2023, CMA has provisionally found competition concerns as part of its in-depth investigation and has kept the deadline for submitting responses to the provisional findings as May 11, 2023. The CMA’s final report is expected by June 5, 2023. Cochlear awaits feedback from the Australian Competition and Consumer Commission and the European Commission as well as the outcome of the review by the French Foreign Direct Investment authority. As a result of the CMA’s findings, the transaction is no longer expected to close before June 30, 2023. As on June 22, 2023, following the report published by UK Competition and Markets Authority, Demant and Cochlear agreed to amend scope of the original transaction, involving the divestment of Demant’s Hearing Implants business, Oticon Medical, to Cochlear Limited. The amended transaction only involves Demant’s cochlear implants (CI) business, whereas the bone anchored hearing systems (BAHS) business is no longer part of the transaction and will thus remain with Demant for now. The UK Competition and Markets Authority published its final report that does not raise competition concerns and is permitted to proceed, subject to the CMA’s approval of the terms of all agreements related to the transfer of the CI business to Cochlear. As on August 2, 2023, CMA proposes to accept the attached proposed Final Undertakings; and proposed Final Undertakings seek to address the SLC identified in the Report and any adverse effects resulting from the SLC. As of August 15, 2023, the acquisition is expected to complete by end December 2023. AS of October 9, 2023, European Commission approved the acquisition of Oticon Medical. As of February 19, 2024, the acquisition is expected to complete by the end of June 2024. As of April 4, 2024, Australian Competition and Consumer Commission decided not to oppose the acquisition of Oticon Medical. Ash Chandhok Tiwari of Baker & Mckenzie LLP acted as legal; advisor to Cochlear. Cochlear Limited (ASX:COH) completed the acquisition of Oticon Medical A/s from Demant A/S (CPSE:DEMANT) on May 21, 2024. The transaction has got all the regulatory and customary closing conditions fulfilled.공시 • Apr 23Cochlear Limited Announces Company Secretary ChangesCochlear Limited announced the appointment of Ms Kristy Jo and Mr. Rob McGrory each as Company Secretary, effective 22 April 2024. These appointments follow the disclosure at the 2023 Annual General Meeting of the pending retirement of Mr. Ray Jarman as Company Secretary, which is effective 22 April 2024. Ms Jo is now the person responsible for communications with the ASX under Listing Rule 12.6.공시 • Apr 20Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-OldCochlear Limited obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™? Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The Osia System is a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the innerear (cochlea). It is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. Now children as young as 5 will be able to have full access to the Osia System's unique technology that is optimized to deliver high power and clarity, especially in high-frequency sounds, which are important for hearing what others are saying. Adrian was diagnosed with hearing loss at age 4 and started with the Baha® Sound Processor with a Baha Softband before transitioning to the Osia System at age 6. The Osia System has been shown to provide clinically significant improvements in high frequency hearing for children.Upcoming Dividend • Mar 14Upcoming dividend of AU$2.00 per shareEligible shareholders must have bought the stock before 21 March 2024. Payment date: 15 April 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Australian dividend payers (6.3%). Lower than average of industry peers (1.6%).Reported Earnings • Feb 20First half 2024 earnings released: EPS: AU$2.92 (vs AU$2.15 in 1H 2023)First half 2024 results: EPS: AU$2.92 (up from AU$2.15 in 1H 2023). Revenue: AU$1.10b (up 24% from 1H 2023). Net income: AU$191.4m (up 35% from 1H 2023). Profit margin: 17% (up from 16% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Sep 11Upcoming dividend of AU$1.75 per share at 1.2% yieldEligible shareholders must have bought the stock before 18 September 2023. Payment date: 11 October 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Australian dividend payers (7.0%). Lower than average of industry peers (1.6%).공시 • Aug 19Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 TCochlear Limited introduced its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The new Osia System offers the proven benefits as the current version: excellent hearing outcomes, ease of use, discreetness and reliability. With the introduction of the OSI300 Implant, it is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. This new patient benefit is made possible by combining the unique properties of the Osia System's Piezo Power™ transducer, which does not contain magnetic material, and the next generation in implant magnet technology. The OSI300 Implant is specifically designed to support access to MRI with no performance degradation after MRI exposure, as there is nothing to be demagnetized as in an electromagnetic transducer. Unlike an axial magnet, which is found in most bone conduction implants and is unsuitable for a patient undergoing an MRI examination at 3.0 T, the OSI300 uses a diametric magnet that sits within a casing and rotates to align with the magnetic field of the MRI machine. The next generation of the Osia System will be available in clinics across the United States this fall and is currently being reviewed by Health Canada. Availability in other countries is subject to regulatory approvals.공시 • Aug 15Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024Cochlear Limited announced that they will report fiscal year 2024 results on Aug 15, 2024Reported Earnings • Aug 15Full year 2023 earnings released: EPS: AU$4.57 (vs AU$4.40 in FY 2022)Full year 2023 results: EPS: AU$4.57 (up from AU$4.40 in FY 2022). Revenue: AU$1.94b (up 18% from FY 2022). Net income: AU$300.6m (up 4.0% from FY 2022). Profit margin: 16% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.공시 • Jul 18Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023Cochlear Limited announced that Non-executive Director Andrew Denver has advised his intention to retire from the Cochlear Board at the end of the next annual general meeting which will be held on 17 October 2023. Mr. Andrew Denver joined the Cochlear Board on 1 February 2007 and has served as a member of the Audit and Risk, Medical Science, Nomination and Product & Services Innovation Committees.Upcoming Dividend • Mar 14Upcoming dividend of AU$1.55 per share at 1.3% yieldEligible shareholders must have bought the stock before 21 March 2023. Payment date: 14 April 2023. Payout ratio is a comfortable 68% and the cash payout ratio is 76%. Trailing yield: 1.3%. Lower than top quartile of Australian dividend payers (7.1%). Lower than average of industry peers (1.7%).공시 • Feb 16+ 1 more updateCochlear Limited Provides Earnings Outlook for the Year 2023Cochlear Limited provided earnings outlook for the year 2023. For the period, the company continue to expect to deliver underlying net profit of $290-305 million, a 5-10% increase on FY22 underlying net profit, an increase of 8-13% when adjusted for the increase in cloud computing-related expenses.공시 • Nov 16Cochlear Limited, Annual General Meeting, Oct 17, 2023Cochlear Limited, Annual General Meeting, Oct 17, 2023.Recent Insider Transactions • Nov 01Key Executive recently bought AU$97k worth of stockOn the 26th of October, Catriona Deans bought around 500 shares on-market at roughly AU$195 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Catriona's only on-market trade for the last 12 months.Upcoming Dividend • Sep 15Upcoming dividend of AU$1.45 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 17 October 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (6.7%). Lower than average of industry peers (1.7%).Reported Earnings • Aug 20Full year 2022 earnings released: EPS: AU$4.40 (vs AU$4.93 in FY 2021)Full year 2022 results: EPS: AU$4.40 (down from AU$4.93 in FY 2021). Revenue: AU$1.65b (up 10% from FY 2021). Net income: AU$289.1m (down 11% from FY 2021). Profit margin: 18% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 14% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.공시 • Apr 15+ 1 more updateCochlear Limited to Report First Half, 2023 Results on Feb 15, 2023Cochlear Limited announced that they will report first half, 2023 results on Feb 15, 2023Upcoming Dividend • Mar 21Upcoming dividend of AU$1.55 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 21 April 2022. Payout ratio is a comfortable 75% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (5.7%). Lower than average of industry peers (1.8%).Reported Earnings • Feb 24First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: EPS: AU$2.57 (down from AU$3.59 in 1H 2021). Revenue: AU$820.7m (up 10% from 1H 2021). Net income: AU$169.3m (down 28% from 1H 2021). Profit margin: 21% (down from 32% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 10%, compared to a 16% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.Recent Insider Transactions • Nov 03Independent Non-Executive Director recently bought AU$56k worth of stockOn the 26th of October, Christine McLoughlin bought around 250 shares on-market at roughly AU$224 per share. In the last 3 months, they made an even bigger purchase worth AU$94k. Insiders have collectively bought AU$314k more in shares than they have sold in the last 12 months.Upcoming Dividend • Sep 16Upcoming dividend of AU$1.40 per shareEligible shareholders must have bought the stock before 23 September 2021. Payment date: 18 October 2021. Trailing yield: 1.2%. Lower than top quartile of Australian dividend payers (5.1%). Lower than average of industry peers (1.7%).공시 • Sep 08Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear ImplantationSensorion and Cochlear Limited announced the initiation of a pilot study of the first-in-class small molecule drug SENS-401 (Arazasetron) in patients scheduled for cochlear implantation. The study will be sponsored by Sensorion and the proposed design is expected to be submitted to the regulatory authorities in the second half of 2021. The results of Sensorion’s in vivo preclinical studies on the use of SENS-401 in conjunction with cochlear transplantation were encouraging. In an established preclinical model, the combination of SENS-401 with cochlear implants preserved residual acoustic hearing at statistically significant levels at a frequency located beyond the electrode array, compared to placebo. In the preclinical study, drug or placebo was delivered via an eluting electrode. The new clinical study will explore the potential efficacy of SENS-401 in combination with cochlear implants.Recent Insider Transactions • Aug 28Independent Non-Executive Director recently bought AU$94k worth of stockOn the 25th of August, Christine McLoughlin bought around 400 shares on-market at roughly AU$235 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$272k more in shares than they have sold in the last 12 months.Executive Departure • Aug 24Independent Chairman Roderic Holliday-Smith has left the companyOn the 20th of August, Roderic Holliday-Smith's tenure as Independent Chairman ended after 16.5 years in the role. We don't have any record of a personal shareholding under Roderic's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.Reported Earnings • Aug 23Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$1.50b (up 13% from FY 2020). Net income: AU$326.5m (up AU$564.8m from FY 2020). Profit margin: 22% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.공시 • Aug 20Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022Cochlear Limited provided earnings guidance for the fiscal year 2022. For the year, the company expects to deliver net profit of $265-285 million, a 12-20% increase on underlying net profit for fiscal year 2021, based on a 74 cent AUD/USD. Sales revenue is expected to benefit from market growth, with a continuing recovery in surgery rates across many countries more affected by COVID.Executive Departure • Jul 20Non-Executive Independent Director Abbas Hussain has left the companyOn the 20th of July, Abbas Hussain's tenure as Non-Executive Independent Director ended after 2.6 years in the role. As of March 2021, Abbas still personally held 1.27k shares (AU$237k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.75 years.공시 • May 04New Cochlear CoPilot app to help adults improve hearing outcomes through skills trainingAdults with cochlear implants may be able to improve their listening and communications skills in daily life with the help of a new self-guided digital tool by Cochlear Limited. Cochlear™ CoPilot is a new mobile app to improve hearing techniques. The app is designed for iPhone® to provide cochlear implant recipients with information, personalized support, and practical tips for hearing, listening and communication all in the palm of their hand. Cochlear CoPilot is designed to be convenient and easy to use; it is free for download from the App Store® now in the United States and Canada.Upcoming Dividend • Mar 18Upcoming Dividend of AU$1.15 Per ShareWill be paid on the 20th of April to those who are registered shareholders by the 25th of March. The trailing yield of 1.1% is below the top quartile of Australian dividend payers (5.5%), and is lower than industry peers (1.4%).공시 • Mar 09Cochlear Receives FDA Clearance of Baha 6 Max, Industry's Smallest 55 dB Sound Processor Now with Direct Android StreamingCochlear Limited announced the U.S. Food and Drug Administration (FDA) clearance of the new Cochlear™ Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people with SSD (single-sided deafness), conductive or mixed hearing loss. With a fitting range of up to 55 dB SNHL (sensorineural hearing level) in the same small size as current 45 dB devices, the Baha 6 Max is the first of its kind: a premium-power bone conduction sound processor designed for powerful hearing performance. The Baha 6 Max is also the first bone conduction sound processor to offer direct streaming from Apple® and Android™ devices. Direct streaming from Apple devices has been available in the Baha 5 Sound Processor since 2015. The new processor provides additional power in the smallest form1,3 and is designed to provide the most clear, rich and natural sound possible–reducing the need to choose between hearing performance and size. Additional improvements of the Baha 6 Max over the previous generation Baha 5 Sound Processor include: New noise and feedback reduction features, Frequency range up to 9.7 kHz Streamlined profile by up to 2 mm, IP68-rating dust and water protection, 50% longer battery life4, Baha Smart App compatibility with Apple Watch®, Child-friendly features, including LED indicator and New mint color option for sound processor front. Improved hearing in noise: Cochlear has more than 40 years of experience in bone conduction hearing solutions, and its market research shows most recipients want to improve their ability to hear in noisy environments. Research suggests extended bandwidth can improve recognition of high-frequency consonants in quiet and in noise7, so the new, high-powered Xidium™ platform in the Baha 6 Max features a frequency range of up to 9.7 kHz. In a study, participants using the Baha 6 Max showed a significant improvement in understanding speech in both quiet and noisy environments compared to the Baha 5 Sound Processor. Cochlear's SmartSound™ iQ signal processing suite boasts new impulse noise reduction and improved feedback management. Along with other features such as the scene classifier and active gain adjustment, this advanced signal processing technology aims to deliver a clear signal, helping the user fully take in their surroundings. The Baha 6 Max showed a significant difference in terms of sound clarity (more than 35% improvement) and sound quality (more than 25% improvement) when compared with the Baha 5 Sound Processor. More power: Usage data from market research suggests many users of bone conduction devices may be underfit, and therefore may benefit from additional dynamic hearing range6, which provides capacity should a person's hearing loss worsen over time. The new BC Drive™ II transducer, which powers the Baha 6 Max, is twice as efficient than the BC Drive on the Baha 5 Sound Processor, delivering 7 dB more average maximum power. Greater connectivity: In addition to being the first bone conduction sound processor with direct audio streaming from Android and Apple devices, the Baha 6 Max is compatible with the Baha Smart App and allows users to connect to an Apple Watch, so they can discreetly fine-tune their sound processor settings. The Smart App also offers additional options to personalize hearing, including the expanded three-band equalizer and settings to customize noise reduction. System readiness: The Baha 6 Max Sound Processor introduces system readiness for expanding connected care portfolio. Designed with children in mind: An LED indicator allows parents, clinicians and carers to be sure the processor is turned on and connected. The small size of the Baha 6 Max makes it a discreet solution for children and adults, and the new LowPro™ snap coupling even brings the device 2 mm closer to the head1, so it sits closer to the head than other bone conduction devices. The Baha 6 Max is also designed to keep up with active children, with its IP68 dust- and water-protection rating. For clinicians, the new Baha Fitting Software 6.0 introduces new workflows to guide fittings, as well as options to customize settings to the child's specific needs. The Baha 6 Max Sound Processor, Baha Fitting Software 6.0 and Baha Smart App are already approved in Canada. The Baha 6 Max Sound Processor will be commercially available across the United States and Canada in the first half of 2021.Recent Insider Transactions • Mar 02Independent Non-Executive Director recently bought AU$164k worth of stockOn the 26th of February, Catriona Deans bought around 786 shares on-market at roughly AU$208 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$397k more in shares than they have sold in the last 12 months.공시 • Feb 24Cochlear Limited Receives US Food and Drug Administration Approval for Baha 6 Max Sound ProcessorCochlear Limited announced it has received US Food and Drug Administration (FDA) clearance and CE Mark accreditation for the new CochlearTM Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people with singlesided deafness, conductive or mixed hearing loss. With a fitting range of up to 55 dB SNHL (sensorineural hearing level) in the same small size as current 45 dB devices1, the Baha 6 Max is the first of its kind: a premiumpower bone conduction sound processor designed for powerful hearing performance. The Baha 6 Max is the first bone conduction sound processor to offer direct streaming from Apple® and AndroidTM devices2. Direct streaming from Apple devices has been available in the Baha 5 Sound Processor since 2015. The new processor provides additional power in the smallest form1,3 and is designed to provide the clearest, richest and most natural sound possible, reducing the need to choose between hearing performance and size.Reported Earnings • Feb 21First half 2021 earnings released: EPS AU$3.59 (vs AU$2.73 in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$743.2m (down 1.7% from 1H 2020). Net income: AU$236.2m (up 50% from 1H 2020). Profit margin: 32% (up from 21% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 20Revenue beats expectationsRevenue exceeded analyst estimates by 6.8%. Over the next year, revenue is forecast to grow 23%, compared to a 27% growth forecast for the Medical Equipment industry in Australia.공시 • Feb 13Cochlear Limited Appoints Stu Sayers as Chief Financial OfficerCochlear Limited advises of the appointment of Stu Sayers as Chief Financial Officer (CFO). Stu has been the President, Services since July 2016, a business that generates around 30% of Cochlear's revenue, and has been a member of the Cochlear executive team since his appointment.Is New 90 Day High Low • Jan 05New 90-day low: AU$189The company is down 10.0% from its price of AU$208 on 08 October 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$172 per share.Is New 90 Day High Low • Dec 22New 90-day low: AU$194The company is down 4.0% from its price of AU$202 on 23 September 2020. The Australian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$173 per share.공시 • Dec 15Cochlear Limited Appoints Stu Sayers as Acting CFOCochlear Limited announced the appointment of Stu Sayers as Acting CFO, effective from 1 January 2021. The permanent appointment of a CFO is expected by 30 June 2021. Stu has been the President, Services since July 2016, a business that generates around 30% of Cochlear's revenue, and has been a member of the Cochlear executive team since his appointment. Stu has a strong financial background and a wealth of experience in establishing and building customer focused technology and online businesses. Stu ran Amazon subsidiary Audible Asia Pacific, E*TRADE and Yahoo!7 in Australia and New Zealand. He previously held senior roles with ANZ, Procter & Gamble and McKinsey. Stu has a Bachelor of Economics and Accounting and an MBA from Wharton.Is New 90 Day High Low • Nov 18New 90-day high: AU$233The company is up 12% from its price of AU$209 on 20 August 2020. The Australian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$141 per share.공시 • Oct 20+ 1 more updateCochlear Limited Appoints Stephen Mayne as DirectorCochlear Limited announced election of Mr. Stephen Mayne as director of the company at the annual general meeting held on October 20, 2020.공시 • Aug 18+ 2 more updatesCochlear Limited to Report Fiscal Year 2021 Results on Aug 20, 2021Cochlear Limited announced that they will report fiscal year 2021 results at 9:33 PM, GMT Standard Time on Aug 20, 2021공시 • Aug 08Cochlear Limited to Report Fiscal Year 2020 Results on Aug 18, 2020Cochlear Limited announced that they will report fiscal year 2020 results at 9:33 PM, GMT Standard Time on Aug 18, 2020주주 수익률COHAU Medical EquipmentAU 시장7D3.1%1.1%0.5%1Y-59.1%-43.0%1.5%전체 주주 수익률 보기수익률 대 산업: COH은 지난 1년 동안 -43%의 수익을 기록한 Australian Medical Equipment 산업보다 저조한 성과를 냈습니다.수익률 대 시장: COH은 지난 1년 동안 1.5%를 기록한 Australian 시장보다 저조한 성과를 냈습니다.주가 변동성Is COH's price volatile compared to industry and market?COH volatilityCOH Average Weekly Movement12.2%Medical Equipment Industry Average Movement9.8%Market Average Movement9.5%10% most volatile stocks in AU Market16.9%10% least volatile stocks in AU Market3.8%안정적인 주가: COH는 지난 3개월 동안 Australian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: COH의 주간 변동성은 지난 1년간 7%에서 12%로 증가했지만 Australian 종목의 상위 75%보다 낮습니다.회사 소개설립직원 수CEO웹사이트19815,500Dig Howittwww.cochlear.com코클리어는 전 세계 어린이와 성인을 위한 이식형 청각 솔루션을 제공합니다. 인공와우 시스템, 사운드 프로세서 업그레이드, 골전도 시스템, 액세서리 및 기타 제품을 제공합니다. 이 회사는 1981년에 설립되었으며 호주 시드니에 본사를 두고 있습니다.더 보기Cochlear Limited 기초 지표 요약Cochlear의 순이익과 매출은 시가총액과 어떻게 비교됩니까?COH 기초 통계시가총액AU$8.09b순이익 (TTM)AU$345.30m매출 (TTM)AU$2.34b23.4x주가수익비율(P/E)3.5x주가매출비율(P/S)COH는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표COH 손익계산서 (TTM)매출AU$2.34b매출원가AU$636.90m총이익AU$1.70b기타 비용AU$1.36b순이익AU$345.30m최근 보고된 실적Dec 31, 2025다음 실적 발표일Aug 18, 2026주당순이익(EPS)5.28총이익률72.76%순이익률14.77%부채/자본 비율0.7%COH의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당3.5%현재 배당 수익률81%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 06:42종가2026/07/09 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cochlear Limited는 26명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Saul HadassinBarrenjoey Markets Pty LimitedStuart RobertsBell PotterElisabeth Decou CliveBernstein23명의 분석가 더 보기
공시 • Feb 13Cochlear Limited Announces an Interim Franked Ordinary Dividend for the Six Months Ended December 31, 2025, Payable on 13 April 2026Cochlear Limited announced an interim franked ordinary dividend of AUD 2.15 per share has been determined for the six months ended December 31, 2025, in line with last year and representing a payout of 72% of underlying net profit. The interim dividend is franked at 85%. The ex-dividend date is 19 March 2026. The record date for calculating dividend entitlements is 20 March 2026 with the interim dividend expected to be paid on 13 April 2026. The ex-date is March 19, 2026, and the record date is March 20, 2026.
공시 • Jan 08Cochlear Announces Availability of Nucleus Nexa System to Us Military VeteransCochlear announced that the Nucleus®? Nexa®? System is now available to eligible US military veterans at VA clinics nationwide. This milestone ensures that veterans with hearing loss have access to Cochlear's most innovative hearing technologies, designed to deliver smarter, more connected hearing experiences. The Nucleus Nexa System is the world's first smart cochlear implant system. The features include upgradeable firmware, internal memory, and with the Power Compact rechargeable battery, is the smallest and lightest sound processor with all day battery life on the market. Paired with the Nucleus 8 Nexa or Kanso®? 3 Nexa sound processors, the system offers intelligent performance that adjusts in real time to changing environments, helping users hear with clarity and comfort.
공시 • Sep 22Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.
Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Non-Executive Director Caroline Clarke was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 15+ 1 more updateCochlear Limited to Report First Half, 2026 Results on Feb 13, 2026Cochlear Limited announced that they will report first half, 2026 results on Feb 13, 2026
공시 • Aug 12Cochlear Limited, Annual General Meeting, Oct 23, 2025Cochlear Limited, Annual General Meeting, Oct 23, 2025. Location: hybrid meeting, Australia
공시 • Feb 13Cochlear Limited Announces an Interim Franked Ordinary Dividend for the Six Months Ended December 31, 2025, Payable on 13 April 2026Cochlear Limited announced an interim franked ordinary dividend of AUD 2.15 per share has been determined for the six months ended December 31, 2025, in line with last year and representing a payout of 72% of underlying net profit. The interim dividend is franked at 85%. The ex-dividend date is 19 March 2026. The record date for calculating dividend entitlements is 20 March 2026 with the interim dividend expected to be paid on 13 April 2026. The ex-date is March 19, 2026, and the record date is March 20, 2026.
공시 • Jan 08Cochlear Announces Availability of Nucleus Nexa System to Us Military VeteransCochlear announced that the Nucleus®? Nexa®? System is now available to eligible US military veterans at VA clinics nationwide. This milestone ensures that veterans with hearing loss have access to Cochlear's most innovative hearing technologies, designed to deliver smarter, more connected hearing experiences. The Nucleus Nexa System is the world's first smart cochlear implant system. The features include upgradeable firmware, internal memory, and with the Power Compact rechargeable battery, is the smallest and lightest sound processor with all day battery life on the market. Paired with the Nucleus 8 Nexa or Kanso®? 3 Nexa sound processors, the system offers intelligent performance that adjusts in real time to changing environments, helping users hear with clarity and comfort.
공시 • Sep 22Cochlear Limited Announces Franked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on October 13, 2025Cochlear Limited announced franked ordinary dividend of AUD 2.15000000 per share for the six months ended June 30, 2025, payable on October 13, 2025. Record Date is September 19, 2025. Ex Date is September 18, 2025.
Board Change • Aug 18Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 3 highly experienced directors. Non-Executive Director Caroline Clarke was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Aug 15+ 1 more updateCochlear Limited to Report First Half, 2026 Results on Feb 13, 2026Cochlear Limited announced that they will report first half, 2026 results on Feb 13, 2026
공시 • Aug 12Cochlear Limited, Annual General Meeting, Oct 23, 2025Cochlear Limited, Annual General Meeting, Oct 23, 2025. Location: hybrid meeting, Australia
공시 • Jul 08Cochlear Limited Launches Smart Cochlear Implant SystemCochlear Limited announced the U.S Food and Drug Administration (FDA) approval of the Cochlear™? Nucleus®? Nexa™? System - the world's first and only smart cochlear implant system. Until now, recipients of cochlear implants have been limited to accessing new technology through the external part of their cochlear implant system - the sound processor - and have typically needed a new sound processor to fully experience the benefits of new technology. The new smart Nexa System has upgradeable implant firmware, which for the first time will enable Cochlear recipients to access future innovation through both their implant and sound processor. Recipients will now have access to their best possible hearing experience with both implant and sound processor updates. The Nucleus Nexa System builds upon Cochlear's portfolio of electrodes, which are designed to optimize the electrode-neural interface and protect cochlear health for a lifetime of hearing performance and opens the door to even greater hearing potential for patients into the future.
공시 • Jun 03Cochlear Limited Introduces the Baha®? 7 Sound Processor and Baha SoundBandCochlear Limited announced the commercial release of the new Cochlear™? Baha®? 7 Sound Processor and the new non-surgical Baha SoundBand™. Cochlear's bone conduction hearing solutions are designed to improve hearing outcomes for children and adults with conductive hearing loss, mixed hearing loss and single-sided deafness (SSD). The Baha 7 Sound Processor builds upon the same great hearing performance of its predecessor while advancing Cochlear's connectivity. The Baha 7 Sound Processor boasts a 55 db HL fitting range in a small form factor, offering powerful hearing without compromising on discretion. With new Bluetooth LE Audio and Auracast broadcast audio compatibility, the Baha 7 Sound Processor leads the hearing implant industry in streaming technology. As more venues adopt Auracast technology, Baha 7 Sound Processor recipients can access audio streams in places like theaters, concert halls, lecture halls and airports, through an LE Audio-enabled smartphone. The Baha 7 Sound processor is also able to stream directly from any compatible Apple® and Android™ device, as well as a range of wireless accessories. non-surgical Baha Start portfolio now includes the Baha 7 Sound Processor and the new Baha SoundBand. Baha Start is designed to help babies and young children experience the fullness of clear, rich and natural sound as early as possible. Early access to sound is critical to helping children learn and develop on par with their hearing peers. The new SoundBand features a slimmer band with improved adjustability, a lower profile, moveable connector discs and more color options to help young children be as comfortable and confident as possible. The Baha Smart App®? and Baha Fitting Software 7 also have new features aimed to help parents and clinicians treat children for the best possible hearing outcomes. The Baha 7 sound Processor and Baha SoundBand will be available in the United States in late summer 2025.
Declared Dividend • Feb 16First half dividend of AU$2.15 announcedShareholders will receive a dividend of AU$2.15. Ex-date: 20th March 2025 Payment date: 14th April 2025 Dividend yield will be 1.6%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (75% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 15First half 2025 earnings released: EPS: AU$3.13 (vs AU$2.92 in 1H 2024)First half 2025 results: EPS: AU$3.13 (up from AU$2.92 in 1H 2024). Revenue: AU$1.17b (up 6.7% from 1H 2024). Net income: AU$205.1m (up 7.2% from 1H 2024). Profit margin: 18% (in line with 1H 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 11% per year.
공시 • Feb 15Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended December 31, 2024, Payable on April 14, 2025Cochlear Limited announced ordinary dividend of AUD 2.15000000 per security for the period of six months ended December 31, 2024. Record date: March 21, 2025. Ex-date: March 20, 2025. Payment date: April 14, 2025.
Buy Or Sell Opportunity • Feb 12Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 3.4% to AU$306. The fair value is estimated to be AU$252, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.9%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Buy Or Sell Opportunity • Oct 01Now 20% overvaluedOver the last 90 days, the stock has fallen 7.3% to AU$292. The fair value is estimated to be AU$243, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 7.9%. For the next 3 years, revenue is forecast to grow by 8.2% per annum. Earnings are also forecast to grow by 11% per annum over the same time period.
공시 • Sep 19+ 1 more updateStu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025Cochlear Limited announced that Stu Sayers, current CFO, will be appointed President, Asia Pacific & Latin America from 1 January 2025.
Upcoming Dividend • Sep 10Upcoming dividend of AU$2.10 per shareEligible shareholders must have bought the stock before 17 September 2024. Payment date: 10 October 2024. Payout ratio and cash payout ratio are on the higher end at 75% and 82% respectively. Trailing yield: 1.5%. Lower than top quartile of Australian dividend payers (6.1%). In line with average of industry peers (1.6%).
공시 • Aug 17+ 1 more updateCochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024Cochlear Limited announced ordinary dividend of AUD 2.10000000 per security for the period of six months ended June 30, 2024. Ex Date is September 17, 2024; Record Date is September 18, 2024; Payment Date is October 10, 2024.
공시 • Aug 15Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.Cochlear Limited (ASX:COH) announces a share repurchase program. Under the program, the company will repurchase up to AUD 75 million worth of its ordinary shares. The program will expire on August 28, 2025. As of August 15, 2024, the company has 65,494,231 shares in issue.
Reported Earnings • Aug 15Full year 2024 earnings released: EPS: AU$5.45 (vs AU$4.57 in FY 2023)Full year 2024 results: EPS: AU$5.45 (up from AU$4.57 in FY 2023). Revenue: AU$2.24b (up 16% from FY 2023). Net income: AU$356.8m (up 19% from FY 2023). Profit margin: 16% (in line with FY 2023). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 7% per year.
공시 • Aug 15+ 1 more updateCochlear Limited, Annual General Meeting, Oct 25, 2024Cochlear Limited, Annual General Meeting, Oct 25, 2024. Location: will be held as a hybrid, Australia
공시 • Jul 30Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024Cochlear Limited (Cochlear) announced the appointment of Caroline Clarke to the Cochlear Board. Ms. Clarke's appointment as a Non-Executive Director will become effective on 2 September 2024. Ms. Clarke has more than 30 years of commercial experience, including 20 years of executive leadership roles at medical devices, medical equipment and healthcare services businesses in large global companies. Ms. Clarke was most recently CEO and Executive Vice President ASEAN Pacific for Philips, responsible for the overall strategy, business and management of the Health Systems and Consumer Personal Health businesses in 14 countries across the region. Caroline is an impressive, people-oriented business leader, driven by making a meaningful impact by improving lives and has demonstrable experience in partnering with leading healthcare institutions to deliver new solutions. Her rounded experience and skills will be invaluable to Cochlear and serve to further enhance the expertise of the Board. Ms. Clarke will become a member of the People and Culture Committee, the Product & Services Innovation Committee and the Nomination Committee. Ms. Clarke holds a bachelor's degree in Business Studies, is a graduate of the Harvard Business School's Advanced Management Program and the Australian Institute of Company Directors, and resides in Sydney, Australia.
공시 • Jul 26Cochlear Limited Announces Executive ChangesCochlear Limited announced a number of changes to the executive team. Richard Brook will be stepping down as President, Europe and Middle East and Africa (EMEA) at the end of December 2024 after more than 20 years in the role. Richard has overseen a period of substantial growth for EMEA, with an eight-fold increase in revenue during that time. Anthony Bishop, current President, Asia Pacific & Latin America, will be appointed President, EMEA from 1 January 2025. Anthony was appointed President, Asia Pacific in July 2016 and took on responsibility for Latin America in June 2021. He has been responsible for the development and execution of the strategic direction for all its operations in Australia, Asia, the South Pacific and Latin America. Prior to Cochlear, Anthony spent 21 years at Johnson & Johnson Medical in various roles, including marketing, sales and general management around the world, including Managing Director, Johnson & Johnson Medical, Australia/New Zealand. Stu Sayers, current Chief Financial Officer, will be appointed President, Asia Pacific & Latin America from 1 January 2025. Stu was appointed as Chief Financial Officer in February 2021 and was previously President, Services since joining Cochlear in July 2016. Prior to Cochlear, Stu led Amazon's subsidiary Audible in Asia Pacific, as well as E*TRADE and Yahoo!7 in Australia and New Zealand. He previously held senior roles with ANZ and McKinsey.
공시 • May 22+ 1 more updateCochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).Cochlear Limited (ASX:COH) agreed to acquire Oticon Medical A/s from Demant A/S (CPSE:DEMANT) for DKK 850 million on April 27, 2022. Of the total consideration of DKK 850 million, DKK 700 million will be paid in cash at closing and DKK 150 million within 18 months after closing. In 2021, Oticon realized revenue of DKK 512 million and Negative EBIT of DKK 117 million. Subject to regulatory approvals and other customary closing conditions and receipt of competition approval. The acquisition is conditional upon approval from each of the CMA, the Australian Competition and Consumer Commission and the European Commission. On October 11, 2022 the CMA launched its phase 1 merger investigation for the acquisition of Oticon Medical A/S. The transaction is expected to close in second half of 2022, following consultation of relevant workers’ councils. As of December 1, 2022, The ACCC has advised a provisional final decision date of March 16, 2023. As on December 7, 2022, The CMA’s competition concerns only relate to the supply of bone conduction solutions in the UK and do not relate to the supply of cochlear implants. Cochlear and Demant have until 13 December to submit undertakings to address the CMA’s competition concerns. As of December 20, 2022, Competition and Markets Authority decided to refer this Merger for a phase 2 investigation. As of April 20, 2023, CMA has provisionally found competition concerns as part of its in-depth investigation and has kept the deadline for submitting responses to the provisional findings as May 11, 2023. The CMA’s final report is expected by June 5, 2023. Cochlear awaits feedback from the Australian Competition and Consumer Commission and the European Commission as well as the outcome of the review by the French Foreign Direct Investment authority. As a result of the CMA’s findings, the transaction is no longer expected to close before June 30, 2023. As on June 22, 2023, following the report published by UK Competition and Markets Authority, Demant and Cochlear agreed to amend scope of the original transaction, involving the divestment of Demant’s Hearing Implants business, Oticon Medical, to Cochlear Limited. The amended transaction only involves Demant’s cochlear implants (CI) business, whereas the bone anchored hearing systems (BAHS) business is no longer part of the transaction and will thus remain with Demant for now. The UK Competition and Markets Authority published its final report that does not raise competition concerns and is permitted to proceed, subject to the CMA’s approval of the terms of all agreements related to the transfer of the CI business to Cochlear. As on August 2, 2023, CMA proposes to accept the attached proposed Final Undertakings; and proposed Final Undertakings seek to address the SLC identified in the Report and any adverse effects resulting from the SLC. As of August 15, 2023, the acquisition is expected to complete by end December 2023. AS of October 9, 2023, European Commission approved the acquisition of Oticon Medical. As of February 19, 2024, the acquisition is expected to complete by the end of June 2024. As of April 4, 2024, Australian Competition and Consumer Commission decided not to oppose the acquisition of Oticon Medical. Ash Chandhok Tiwari of Baker & Mckenzie LLP acted as legal; advisor to Cochlear. Cochlear Limited (ASX:COH) completed the acquisition of Oticon Medical A/s from Demant A/S (CPSE:DEMANT) on May 21, 2024. The transaction has got all the regulatory and customary closing conditions fulfilled.
공시 • Apr 23Cochlear Limited Announces Company Secretary ChangesCochlear Limited announced the appointment of Ms Kristy Jo and Mr. Rob McGrory each as Company Secretary, effective 22 April 2024. These appointments follow the disclosure at the 2023 Annual General Meeting of the pending retirement of Mr. Ray Jarman as Company Secretary, which is effective 22 April 2024. Ms Jo is now the person responsible for communications with the ASX under Listing Rule 12.6.
공시 • Apr 20Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-OldCochlear Limited obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™? Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The Osia System is a new category of bone conduction hearing solutions that uses digital piezoelectric stimulation to bypass damaged areas of the natural hearing system to send sound vibrations directly to the innerear (cochlea). It is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. Now children as young as 5 will be able to have full access to the Osia System's unique technology that is optimized to deliver high power and clarity, especially in high-frequency sounds, which are important for hearing what others are saying. Adrian was diagnosed with hearing loss at age 4 and started with the Baha® Sound Processor with a Baha Softband before transitioning to the Osia System at age 6. The Osia System has been shown to provide clinically significant improvements in high frequency hearing for children.
Upcoming Dividend • Mar 14Upcoming dividend of AU$2.00 per shareEligible shareholders must have bought the stock before 21 March 2024. Payment date: 15 April 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Australian dividend payers (6.3%). Lower than average of industry peers (1.6%).
Reported Earnings • Feb 20First half 2024 earnings released: EPS: AU$2.92 (vs AU$2.15 in 1H 2023)First half 2024 results: EPS: AU$2.92 (up from AU$2.15 in 1H 2023). Revenue: AU$1.10b (up 24% from 1H 2023). Net income: AU$191.4m (up 35% from 1H 2023). Profit margin: 17% (up from 16% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Sep 11Upcoming dividend of AU$1.75 per share at 1.2% yieldEligible shareholders must have bought the stock before 18 September 2023. Payment date: 11 October 2023. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Australian dividend payers (7.0%). Lower than average of industry peers (1.6%).
공시 • Aug 19Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 TCochlear Limited introduced its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD). The new Osia System offers the proven benefits as the current version: excellent hearing outcomes, ease of use, discreetness and reliability. With the introduction of the OSI300 Implant, it is the first and only active bone conduction system that allows patients to undergo MRI scans at both 1.5 T and 3.0 T without the need for surgery. This new patient benefit is made possible by combining the unique properties of the Osia System's Piezo Power™ transducer, which does not contain magnetic material, and the next generation in implant magnet technology. The OSI300 Implant is specifically designed to support access to MRI with no performance degradation after MRI exposure, as there is nothing to be demagnetized as in an electromagnetic transducer. Unlike an axial magnet, which is found in most bone conduction implants and is unsuitable for a patient undergoing an MRI examination at 3.0 T, the OSI300 uses a diametric magnet that sits within a casing and rotates to align with the magnetic field of the MRI machine. The next generation of the Osia System will be available in clinics across the United States this fall and is currently being reviewed by Health Canada. Availability in other countries is subject to regulatory approvals.
공시 • Aug 15Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024Cochlear Limited announced that they will report fiscal year 2024 results on Aug 15, 2024
Reported Earnings • Aug 15Full year 2023 earnings released: EPS: AU$4.57 (vs AU$4.40 in FY 2022)Full year 2023 results: EPS: AU$4.57 (up from AU$4.40 in FY 2022). Revenue: AU$1.94b (up 18% from FY 2022). Net income: AU$300.6m (up 4.0% from FY 2022). Profit margin: 16% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
공시 • Jul 18Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023Cochlear Limited announced that Non-executive Director Andrew Denver has advised his intention to retire from the Cochlear Board at the end of the next annual general meeting which will be held on 17 October 2023. Mr. Andrew Denver joined the Cochlear Board on 1 February 2007 and has served as a member of the Audit and Risk, Medical Science, Nomination and Product & Services Innovation Committees.
Upcoming Dividend • Mar 14Upcoming dividend of AU$1.55 per share at 1.3% yieldEligible shareholders must have bought the stock before 21 March 2023. Payment date: 14 April 2023. Payout ratio is a comfortable 68% and the cash payout ratio is 76%. Trailing yield: 1.3%. Lower than top quartile of Australian dividend payers (7.1%). Lower than average of industry peers (1.7%).
공시 • Feb 16+ 1 more updateCochlear Limited Provides Earnings Outlook for the Year 2023Cochlear Limited provided earnings outlook for the year 2023. For the period, the company continue to expect to deliver underlying net profit of $290-305 million, a 5-10% increase on FY22 underlying net profit, an increase of 8-13% when adjusted for the increase in cloud computing-related expenses.
공시 • Nov 16Cochlear Limited, Annual General Meeting, Oct 17, 2023Cochlear Limited, Annual General Meeting, Oct 17, 2023.
Recent Insider Transactions • Nov 01Key Executive recently bought AU$97k worth of stockOn the 26th of October, Catriona Deans bought around 500 shares on-market at roughly AU$195 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Catriona's only on-market trade for the last 12 months.
Upcoming Dividend • Sep 15Upcoming dividend of AU$1.45 per shareEligible shareholders must have bought the stock before 22 September 2022. Payment date: 17 October 2022. Payout ratio is a comfortable 68% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (6.7%). Lower than average of industry peers (1.7%).
Reported Earnings • Aug 20Full year 2022 earnings released: EPS: AU$4.40 (vs AU$4.93 in FY 2021)Full year 2022 results: EPS: AU$4.40 (down from AU$4.93 in FY 2021). Revenue: AU$1.65b (up 10% from FY 2021). Net income: AU$289.1m (down 11% from FY 2021). Profit margin: 18% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 14% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
공시 • Apr 15+ 1 more updateCochlear Limited to Report First Half, 2023 Results on Feb 15, 2023Cochlear Limited announced that they will report first half, 2023 results on Feb 15, 2023
Upcoming Dividend • Mar 21Upcoming dividend of AU$1.55 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 21 April 2022. Payout ratio is a comfortable 75% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (5.7%). Lower than average of industry peers (1.8%).
Reported Earnings • Feb 24First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: EPS: AU$2.57 (down from AU$3.59 in 1H 2021). Revenue: AU$820.7m (up 10% from 1H 2021). Net income: AU$169.3m (down 28% from 1H 2021). Profit margin: 21% (down from 32% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 10%, compared to a 16% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Nov 03Independent Non-Executive Director recently bought AU$56k worth of stockOn the 26th of October, Christine McLoughlin bought around 250 shares on-market at roughly AU$224 per share. In the last 3 months, they made an even bigger purchase worth AU$94k. Insiders have collectively bought AU$314k more in shares than they have sold in the last 12 months.
Upcoming Dividend • Sep 16Upcoming dividend of AU$1.40 per shareEligible shareholders must have bought the stock before 23 September 2021. Payment date: 18 October 2021. Trailing yield: 1.2%. Lower than top quartile of Australian dividend payers (5.1%). Lower than average of industry peers (1.7%).
공시 • Sep 08Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear ImplantationSensorion and Cochlear Limited announced the initiation of a pilot study of the first-in-class small molecule drug SENS-401 (Arazasetron) in patients scheduled for cochlear implantation. The study will be sponsored by Sensorion and the proposed design is expected to be submitted to the regulatory authorities in the second half of 2021. The results of Sensorion’s in vivo preclinical studies on the use of SENS-401 in conjunction with cochlear transplantation were encouraging. In an established preclinical model, the combination of SENS-401 with cochlear implants preserved residual acoustic hearing at statistically significant levels at a frequency located beyond the electrode array, compared to placebo. In the preclinical study, drug or placebo was delivered via an eluting electrode. The new clinical study will explore the potential efficacy of SENS-401 in combination with cochlear implants.
Recent Insider Transactions • Aug 28Independent Non-Executive Director recently bought AU$94k worth of stockOn the 25th of August, Christine McLoughlin bought around 400 shares on-market at roughly AU$235 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$272k more in shares than they have sold in the last 12 months.
Executive Departure • Aug 24Independent Chairman Roderic Holliday-Smith has left the companyOn the 20th of August, Roderic Holliday-Smith's tenure as Independent Chairman ended after 16.5 years in the role. We don't have any record of a personal shareholding under Roderic's name. A total of 4 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.
Reported Earnings • Aug 23Full year 2021 earnings released: EPS AU$4.97 (vs AU$4.00 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$1.50b (up 13% from FY 2020). Net income: AU$326.5m (up AU$564.8m from FY 2020). Profit margin: 22% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
공시 • Aug 20Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2022Cochlear Limited provided earnings guidance for the fiscal year 2022. For the year, the company expects to deliver net profit of $265-285 million, a 12-20% increase on underlying net profit for fiscal year 2021, based on a 74 cent AUD/USD. Sales revenue is expected to benefit from market growth, with a continuing recovery in surgery rates across many countries more affected by COVID.
Executive Departure • Jul 20Non-Executive Independent Director Abbas Hussain has left the companyOn the 20th of July, Abbas Hussain's tenure as Non-Executive Independent Director ended after 2.6 years in the role. As of March 2021, Abbas still personally held 1.27k shares (AU$237k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.75 years.
공시 • May 04New Cochlear CoPilot app to help adults improve hearing outcomes through skills trainingAdults with cochlear implants may be able to improve their listening and communications skills in daily life with the help of a new self-guided digital tool by Cochlear Limited. Cochlear™ CoPilot is a new mobile app to improve hearing techniques. The app is designed for iPhone® to provide cochlear implant recipients with information, personalized support, and practical tips for hearing, listening and communication all in the palm of their hand. Cochlear CoPilot is designed to be convenient and easy to use; it is free for download from the App Store® now in the United States and Canada.
Upcoming Dividend • Mar 18Upcoming Dividend of AU$1.15 Per ShareWill be paid on the 20th of April to those who are registered shareholders by the 25th of March. The trailing yield of 1.1% is below the top quartile of Australian dividend payers (5.5%), and is lower than industry peers (1.4%).
공시 • Mar 09Cochlear Receives FDA Clearance of Baha 6 Max, Industry's Smallest 55 dB Sound Processor Now with Direct Android StreamingCochlear Limited announced the U.S. Food and Drug Administration (FDA) clearance of the new Cochlear™ Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people with SSD (single-sided deafness), conductive or mixed hearing loss. With a fitting range of up to 55 dB SNHL (sensorineural hearing level) in the same small size as current 45 dB devices, the Baha 6 Max is the first of its kind: a premium-power bone conduction sound processor designed for powerful hearing performance. The Baha 6 Max is also the first bone conduction sound processor to offer direct streaming from Apple® and Android™ devices. Direct streaming from Apple devices has been available in the Baha 5 Sound Processor since 2015. The new processor provides additional power in the smallest form1,3 and is designed to provide the most clear, rich and natural sound possible–reducing the need to choose between hearing performance and size. Additional improvements of the Baha 6 Max over the previous generation Baha 5 Sound Processor include: New noise and feedback reduction features, Frequency range up to 9.7 kHz Streamlined profile by up to 2 mm, IP68-rating dust and water protection, 50% longer battery life4, Baha Smart App compatibility with Apple Watch®, Child-friendly features, including LED indicator and New mint color option for sound processor front. Improved hearing in noise: Cochlear has more than 40 years of experience in bone conduction hearing solutions, and its market research shows most recipients want to improve their ability to hear in noisy environments. Research suggests extended bandwidth can improve recognition of high-frequency consonants in quiet and in noise7, so the new, high-powered Xidium™ platform in the Baha 6 Max features a frequency range of up to 9.7 kHz. In a study, participants using the Baha 6 Max showed a significant improvement in understanding speech in both quiet and noisy environments compared to the Baha 5 Sound Processor. Cochlear's SmartSound™ iQ signal processing suite boasts new impulse noise reduction and improved feedback management. Along with other features such as the scene classifier and active gain adjustment, this advanced signal processing technology aims to deliver a clear signal, helping the user fully take in their surroundings. The Baha 6 Max showed a significant difference in terms of sound clarity (more than 35% improvement) and sound quality (more than 25% improvement) when compared with the Baha 5 Sound Processor. More power: Usage data from market research suggests many users of bone conduction devices may be underfit, and therefore may benefit from additional dynamic hearing range6, which provides capacity should a person's hearing loss worsen over time. The new BC Drive™ II transducer, which powers the Baha 6 Max, is twice as efficient than the BC Drive on the Baha 5 Sound Processor, delivering 7 dB more average maximum power. Greater connectivity: In addition to being the first bone conduction sound processor with direct audio streaming from Android and Apple devices, the Baha 6 Max is compatible with the Baha Smart App and allows users to connect to an Apple Watch, so they can discreetly fine-tune their sound processor settings. The Smart App also offers additional options to personalize hearing, including the expanded three-band equalizer and settings to customize noise reduction. System readiness: The Baha 6 Max Sound Processor introduces system readiness for expanding connected care portfolio. Designed with children in mind: An LED indicator allows parents, clinicians and carers to be sure the processor is turned on and connected. The small size of the Baha 6 Max makes it a discreet solution for children and adults, and the new LowPro™ snap coupling even brings the device 2 mm closer to the head1, so it sits closer to the head than other bone conduction devices. The Baha 6 Max is also designed to keep up with active children, with its IP68 dust- and water-protection rating. For clinicians, the new Baha Fitting Software 6.0 introduces new workflows to guide fittings, as well as options to customize settings to the child's specific needs. The Baha 6 Max Sound Processor, Baha Fitting Software 6.0 and Baha Smart App are already approved in Canada. The Baha 6 Max Sound Processor will be commercially available across the United States and Canada in the first half of 2021.
Recent Insider Transactions • Mar 02Independent Non-Executive Director recently bought AU$164k worth of stockOn the 26th of February, Catriona Deans bought around 786 shares on-market at roughly AU$208 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$397k more in shares than they have sold in the last 12 months.
공시 • Feb 24Cochlear Limited Receives US Food and Drug Administration Approval for Baha 6 Max Sound ProcessorCochlear Limited announced it has received US Food and Drug Administration (FDA) clearance and CE Mark accreditation for the new CochlearTM Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people with singlesided deafness, conductive or mixed hearing loss. With a fitting range of up to 55 dB SNHL (sensorineural hearing level) in the same small size as current 45 dB devices1, the Baha 6 Max is the first of its kind: a premiumpower bone conduction sound processor designed for powerful hearing performance. The Baha 6 Max is the first bone conduction sound processor to offer direct streaming from Apple® and AndroidTM devices2. Direct streaming from Apple devices has been available in the Baha 5 Sound Processor since 2015. The new processor provides additional power in the smallest form1,3 and is designed to provide the clearest, richest and most natural sound possible, reducing the need to choose between hearing performance and size.
Reported Earnings • Feb 21First half 2021 earnings released: EPS AU$3.59 (vs AU$2.73 in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$743.2m (down 1.7% from 1H 2020). Net income: AU$236.2m (up 50% from 1H 2020). Profit margin: 32% (up from 21% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 20Revenue beats expectationsRevenue exceeded analyst estimates by 6.8%. Over the next year, revenue is forecast to grow 23%, compared to a 27% growth forecast for the Medical Equipment industry in Australia.
공시 • Feb 13Cochlear Limited Appoints Stu Sayers as Chief Financial OfficerCochlear Limited advises of the appointment of Stu Sayers as Chief Financial Officer (CFO). Stu has been the President, Services since July 2016, a business that generates around 30% of Cochlear's revenue, and has been a member of the Cochlear executive team since his appointment.
Is New 90 Day High Low • Jan 05New 90-day low: AU$189The company is down 10.0% from its price of AU$208 on 08 October 2020. The Australian market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$172 per share.
Is New 90 Day High Low • Dec 22New 90-day low: AU$194The company is down 4.0% from its price of AU$202 on 23 September 2020. The Australian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$173 per share.
공시 • Dec 15Cochlear Limited Appoints Stu Sayers as Acting CFOCochlear Limited announced the appointment of Stu Sayers as Acting CFO, effective from 1 January 2021. The permanent appointment of a CFO is expected by 30 June 2021. Stu has been the President, Services since July 2016, a business that generates around 30% of Cochlear's revenue, and has been a member of the Cochlear executive team since his appointment. Stu has a strong financial background and a wealth of experience in establishing and building customer focused technology and online businesses. Stu ran Amazon subsidiary Audible Asia Pacific, E*TRADE and Yahoo!7 in Australia and New Zealand. He previously held senior roles with ANZ, Procter & Gamble and McKinsey. Stu has a Bachelor of Economics and Accounting and an MBA from Wharton.
Is New 90 Day High Low • Nov 18New 90-day high: AU$233The company is up 12% from its price of AU$209 on 20 August 2020. The Australian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$141 per share.
공시 • Oct 20+ 1 more updateCochlear Limited Appoints Stephen Mayne as DirectorCochlear Limited announced election of Mr. Stephen Mayne as director of the company at the annual general meeting held on October 20, 2020.
공시 • Aug 18+ 2 more updatesCochlear Limited to Report Fiscal Year 2021 Results on Aug 20, 2021Cochlear Limited announced that they will report fiscal year 2021 results at 9:33 PM, GMT Standard Time on Aug 20, 2021
공시 • Aug 08Cochlear Limited to Report Fiscal Year 2020 Results on Aug 18, 2020Cochlear Limited announced that they will report fiscal year 2020 results at 9:33 PM, GMT Standard Time on Aug 18, 2020
